Health Care
Medical innovation and specified charges
Johnson & Johnson reports medicines and medical technology alongside material adjustments to earnings. Product sales, acquisition activity and litigation charges answer different analytical questions.
The reporting context
Johnson & Johnson reports medicines and medical technology alongside material adjustments to earnings. Product sales, acquisition activity and litigation charges answer different analytical questions.
Reported observations
Johnson & Johnson (JNJ) — Q3 2026, ended 2026-09-27, released 2026-10-13: Sales 25,399 USD million; Net earnings 210 USD million; Diluted EPS 0.09 USD/share.
Interpretation
Read the reported-to-adjusted bridge and retain its accounting labels. Regional sales and segment sales are alternative breakdowns of the same total, not additive populations. Reported and adjusted earnings differ materially in the quarter. That gap makes the adjustment schedule essential reading rather than an optional footnote. Business sales and acquisition or litigation charges describe different aspects of performance and should not be collapsed into one growth claim.
What the comparison does not establish
This issuer case does not represent insurers or the whole health-care industry. Future guidance is separate from the quarter already reported.
Data method
This edition uses the latest quarterly earnings results located in official sources as of November 15, 2026. Each company page shows its own period end and release date, selected metrics, units and accounting basis. Amounts shown as rounded remain rounded. Analysis is editorial interpretation of the linked disclosures, not issuer guidance, price forecasts or personalized advice.